Document is current
Any future updates will be listed below
-
Authors
Cadeddu, Roberto
Van Zandt, Meghan
Santovito, Luca Spiro
Odeh, Karen
Anderson, Collin J.
Flanagan, Deirdre
Nordkild, Peter
Pinna, Graziano https://orcid.org/0000-0001-7541-4855
Pittenger, Christopher https://orcid.org/0000-0003-2117-9321
Bortolato, Marco
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R21 NS108722, R21 NS125654)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- License Information
-
More Information
Article History
Received: 5 November 2022
Revised: 24 April 2023
Accepted: 5 May 2023
First Online: 17 May 2023
Competing interests
: PN is CEO and CMO for Asarina Pharma, has a 1.2% equity stake in Asarina Pharma, and has filed patents for the use of sepranolone in the treatment of Tourette syndrome, obsessive-compulsive disorder, and pathological gambling. GP is a paid consultant to PureTech Health, GABA Therapeutics, and NeuroTrauma Sciences. He has a pending patent application on N-palmitoylethanolamine (PEA) and peroxisome proliferator-activated receptor alpha (PPAR-α) agonists, and another one on allopregnanolone analogs US11266663B2 granted on March 8, 2022 in the treatment of neuropsychiatric disorders. CP consults for Biohaven Pharmaceuticals, Ceruvia Lifesciences, Transcend Therapeutics, Freedom Biosciences, Nobilis Therapeutics, and UCB Biopharma and receives research funding from Biohaven, Transcend, and Freedom. He has filed patents for neurofeedback and psychedelics in the treatment of obsessive-compulsive disorder, unrelated to the current work. MB consults for Asarina Pharmaceuticals and receives research funding from Asarina and Lundbeck Pharmaceuticals. The other authors declare no conflict of interest.
